Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTICCA-1 adjuvant gemcitabine/cisplatin versus standard of care after curative resection of biliary tract cancer
NL-OMON60838Phase 3Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Nov 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, cisplatin and capecitabine in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Disease-free survival. Started Nov 2024; status: completed.
02
Drugs
gemcitabinecisplatincapecitabine
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NL-OMON60838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60838.